SCHEMBL21112948

SCHEMBL21112948

COc1cc(C(=O)O[C@H]2[C@@H](OC)O[C@H](CO)[C@@H](O)[C@@H]2O)ccc1Oc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.49
LGALS3 P17931 7/20 0.48
LGALS8 O00214 4/20 0.48
LGALS9 O00182 4/20 0.48
LGALS1 P09382 4/20 0.48
LGALS7; LGALS7B P47929 4/20 0.48
LGALS4 P56470 3/20 0.47
ACHE P22303 1/20 0.43
SNCA P37840 1/20 0.43
PTPN1 P18031 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24145071 0.92 TTR (0.49) TTRLGALS3LGALS8LGALS9LGALS1
SCHEMBL23488620 0.89 LGALS3 (0.49) LGALS3LGALS8LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL23488494 0.87 NPC1 (0.50) LGALS3LGALS8LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL23488437 0.85 LGALS3 (0.44) LGALS3LGALS8LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL24137795 0.85 LGALS8 (0.45) LGALS3LGALS8LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL23488285 0.83 LGALS3 (0.45) LGALS3LGALS8LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL11371729 0.82 LGALS3 (0.60) LGALS3LGALS8LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL11368063 0.82 LGALS3 (0.60) LGALS3LGALS8LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL21112942 0.80 TDP1 (0.56) TTRACHE
SCHEMBL23488490 0.79 LGALS3 (0.53) LGALS3LGALS8LGALS9LGALS1LGALS7; LGALS7B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 US disclosed
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 US disclosed
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein GPR119, SLC2A8, SLC2A4 TTR 1676/4885LGALS3 210/4885LGALS8 98/4885
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 TTR 1676/4885LGALS3 210/4885LGALS8 98/4885
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 TTR 1676/4885LGALS3 210/4885LGALS8 98/4885
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 TTR 1676/4885LGALS3 210/4885LGALS8 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.